- Market cap
- $2.61B
- 52w range
- $11.55 - $30.06
- Beta
- 2.07
- Sector
- Healthcare
- Data quality
- 75/100
- fair value estimate
- $9.23
- Margin of safety
- -55.8%
- Moat score
- 15/100
- Return on equity
- -50.1%
- Debt / equity
- 0.01
- Analyst target
- $35.77
- Target upside
- +71.2%
- Analysts
- 13
About Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Valuation
Derived from filed metrics · High confidence (75% of the inputs available)
Moat, fair value and rating computed by our valuation engine (ported from the original Python model).